Newman Dignan & Sheerar Inc. Purchases 9,370 Shares of Invesco Biotechnology & Genome ETF $PBE

Newman Dignan & Sheerar Inc. purchased a new position in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 9,370 shares of the company’s stock, valued at approximately $912,000.

A number of other institutional investors have also modified their holdings of the stock. Royal Bank of Canada lifted its holdings in shares of Invesco Biotechnology & Genome ETF by 25.9% in the 1st quarter. Royal Bank of Canada now owns 59,329 shares of the company’s stock valued at $4,698,000 after buying an additional 12,215 shares during the period. YHB Investment Advisors Inc. purchased a new position in Invesco Biotechnology & Genome ETF during the third quarter valued at approximately $2,169,000. Envestnet Asset Management Inc. lifted its holdings in Invesco Biotechnology & Genome ETF by 4.2% in the second quarter. Envestnet Asset Management Inc. now owns 22,250 shares of the company’s stock valued at $1,995,000 after acquiring an additional 888 shares during the period. Cetera Investment Advisers lifted its holdings in Invesco Biotechnology & Genome ETF by 2.0% in the first quarter. Cetera Investment Advisers now owns 23,139 shares of the company’s stock valued at $1,832,000 after acquiring an additional 464 shares during the period. Finally, Rockefeller Capital Management L.P. lifted its holdings in Invesco Biotechnology & Genome ETF by 6.7% in the fourth quarter. Rockefeller Capital Management L.P. now owns 10,666 shares of the company’s stock valued at $876,000 after acquiring an additional 666 shares during the period.

Invesco Biotechnology & Genome ETF Trading Up 2.6%

Invesco Biotechnology & Genome ETF stock opened at $99.22 on Wednesday. The firm has a market cap of $430.61 million, a PE ratio of 20.44 and a beta of 0.70. Invesco Biotechnology & Genome ETF has a 12 month low of $72.27 and a 12 month high of $99.75. The stock’s 50 day simple moving average is $96.17 and its two-hundred day simple moving average is $89.13.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.